Climb Bio
CLYM
68 hedge funds and large institutions have $89.7M invested in Climb Bio in 2025 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 12 increasing their positions, 34 reducing their positions, and 13 closing their positions.
8% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 13
1% less funds holding
Funds holding: 69 → 68 (-1)
7.96% less ownership
Funds ownership: 73.83% → 65.87% (-8%)
65% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 34
85% less capital inflows, than outflows
Capital inflows: $1.67M | Capital outflows: $11.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sphera Funds Management
Tel Aviv,
Israel
|
+$418K |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$359K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$149K |
| 4 |
LPL Financial
San Diego,
California
|
+$113K |
| 5 |
BCM
Bluefin Capital Management
New York
|
+$111K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cantor Fitzgerald
New York
|
-$3.63M |
| 2 |
Citigroup
New York
|
-$2.38M |
| 3 |
Diadema Partners
Morristown,
New Jersey
|
-$1.05M |
| 4 |
Deep Track Capital
Greenwich,
Connecticut
|
-$985K |
| 5 |
Shay Capital
New York
|
-$492K |
CLYM Hedge Fund Activity: Q3 2025 in Review
68 of the 7,656 institutional investors tracked by Wall St. Rank reported a position in Climb Bio (CLYM) for Q3 2025, worth a combined $89.7M — up 45% from $61.9M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of CLYM and 12 opened new positions — a net loss of 1 holder — while 34 trimmed existing stakes and 12 added.
The largest buyer was Sphera Funds Management, adding an estimated $418K. The largest seller was Cantor Fitzgerald, cutting an estimated $3.63M.
- 68 institutional investors held Climb Bio (CLYM) as of Q3 2025, down from 69 in Q2 2025.
- Funds reported $89.7M of Climb Bio stock for Q3 2025, up 45% quarter-over-quarter.
- 12 funds opened new Climb Bio positions in Q3 2025 and 13 closed out, a net change of -1 holder.
- The largest Climb Bio buyer in Q3 2025 was Sphera Funds Management, an estimated $418K added.
- The largest Climb Bio seller in Q3 2025 was Cantor Fitzgerald, an estimated $3.63M sold.
Based on aggregated 13F filings for Q3 2025.